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The past 15 years have witnessed a remarkable expan-sion in noninvasive cardiovascular imaging technology. 
Indeed, we now have access to a wide spectrum of modalities, 
each offering distinct and potentially complementary informa-
tion with respect to the pathophysiology of atherosclerosis. 
Considerable interest has surrounded the use of this technol-
ogy to improve cardiovascular risk prediction so that we can 
better identify high-risk patients, allowing us to intervene and 
avert subsequent myocardial infarction. For many years, the 
major focus in atherosclerosis imaging research has been to 
identify individual coronary plaques at high risk of rupture, 
the so-called vulnerable plaque. Ultimately, this strategy has 
failed to have a major impact on clinical care, prompting many 
to consider a switch of emphasis to pan-coronary and pan-vas-
cular assessments of disease activity that may be more closely 
related to the vulnerable patient: those subjects at highest risk 
of cardiovascular events.1 This review will describe novel 
noninvasive imaging strategies developed to tackle this issue; 
in particular, how the measures of disease activity targeted 
to both inflammation and microcalcification might be used 
to identify patients at highest risk of stroke and myocardial 
infarction.
Review
Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.116.307971
Abstract: Major focus has been placed on the identification of vulnerable plaques as a means of improving the 
prediction of myocardial infarction. However, this strategy has recently been questioned on the basis that the 
majority of these individual coronary lesions do not in fact go on to cause clinical events. Attention is, therefore, 
shifting to alternative imaging modalities that might provide a more complete pan-coronary assessment of the 
atherosclerotic disease process. These include markers of disease activity with the potential to discriminate between 
patients with stable burnt-out disease that is no longer metabolically active and those with active atheroma, faster 
disease progression, and increased risk of infarction. This review will examine how novel molecular imaging 
approaches can provide such assessments, focusing on inflammation and microcalcification activity, the importance 
of these processes to coronary atherosclerosis, and the advantages and challenges posed by these techniques.  (Circ 
Res. 2016;119:330-340. DOI: 10.1161/CIRCRESAHA.116.307971.)
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Problems With the Vulnerable Plaque Paradigm
The majority of acute coronary events are because of athero-
sclerotic plaque rupture. However, identifying plaques at risk 
of rupture, the so-called vulnerable plaque, has proved prob-
lematic. The majority of plaques causing myocardial infarc-
tion are nonobstructive on antecedent coronary angiography,2,3 
and up to one third of ruptured plaques demonstrate <75% 
cross-sectional vascular area narrowing at postmortem.3 These 
lesions are, therefore, frequently missed on angiography and 
stress testing, prompting interest in novel imaging strategies 
that might better predict myocardial infarction. Histological 
studies have consistently associated several key adverse plaque 
characteristics with rupture and myocardial infarction. These 
include a thin fibrous cap, macrophage infiltration, a large 
necrotic core and plaque volume, microcalcification, angio-
genesis, and intraplaque hemorrhage. These features are often 
observed in constellation in lesions known as thin-capped fi-
broatheroma, with each feature representing a potential imag-
ing target for identifying plaque vulnerability regardless of the 
extent of luminal stenosis. Indeed, this has been the subject of 
intense research over the past 10 to 15 years and the principle 
underlying the development of numerous invasive and nonin-
vasive imaging techniques (Figure 1). However, to date this 
approach has failed to affect the clinical practice.
The PROSPECT trial (A Prospective Natural-History 
Study of Coronary Atherosclerosis) investigated whether 
the detection of thin-capped fibroatheroma by virtual histol-
ogy intravascular ultrasound would predict adverse clinical 
events.4 In this study, 595 virtual histology intravascular ultra-
sound–defined thin-capped fibroatheromas were identified in 
697 patients; however, after a median follow-up of 3.4 years, 
only 6 lesions resulted in myocardial infarction. Similarly, the 
VIVA study (VH-IVUS in Vulnerable Atherosclerosis) iden-
tified 550 virtual histology–thin-capped fibroatheromas with 
only 8 resulting in a major adverse cardiovascular event not 
related to stent restenosis.5 Indeed, the low predictive value of 
individual plaques progressing to cause events has emerged 
as the major limitation with the vulnerable plaque strategy.6,7 
Although imaging and histological studies conducted post 
myocardial infarction have demonstrated that the above ad-
verse characteristics have consistently been associated with 
culprit and ruptured plaques, prospective observational stud-
ies have shown that such plaques are, in fact, relatively com-
mon but go on to cause myocardial infarction in only a small 
minority of cases.8
Why then do vulnerable plaques outnumber the cardiac 
events that they cause? The answer lies in the natural history 
of these lesions (Figure 1). First, the majority of these in-
flamed high-risk lesions are likely to heal and stabilize with 
time rather than rupture. In particular, progressive calcifi-
cation sees the transition from the early stages of high-risk 
microcalcification to the stable end stages of macroscopic cal-
cification.9 Second, even in those lesions where the healing 
process is unsuccessful and plaque rupture occurs, the major-
ity of these events seem to be subclinical, resulting in silent 
plaque growth, rather than myocardial infarction.8,10 Indeed, 
evidence of old healed plaque rupture is seen in more than 
four fifths of lesions with >50% luminal stenosis.10 As a con-
sequence, although retrospective studies demonstrate that vul-
nerable plaques are consistently responsible for myocardial 
infarction, prospective studies indicate that only a minority of 
these supposedly high-risk plaques proceed to cause clinically 
apparent events. The worth of identifying vulnerable plaques 
has, therefore, been questioned indeed if the majority go on to 
cause no harm, how can their treatment be justified?8,11
Targeting the Vulnerable Patient
Strategies focused on broader patient-related factors have 
proved more effective. Cardiovascular risk scores, such as the 
Framingham risk score (FRS), have been used for several de-
cades to estimate a patient’s risk of having a cardiovascular 
event based on well-established epidemiological studies and 
the presence of cardiovascular risk factors, such as age, dia-
betes mellitus, hypertension, and smoking. Although useful 
on a population level, the accuracy of predicting a patient’s 
individual risk is limited. Interest has, therefore, surrounded 
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Figure 1. Natural history of the vulnerable plaque. 
Vulnerable atherosclerotic plaques are thought to account for 
the majority of myocardial infarctions and are characterized 
by macrophage inflammation, a thin fibrous cap, positive 
remodeling, microcalcification, and angiogenesis. Histological 
and imaging studies conducted post myocardial infarction (MI) 
have consistently associated these plaques with rupture and 
myocardial infarction. However, in prospective observational 
studies, only a minority of these plaques go on to cause adverse 
clinical events (red arrows). This is because many vulnerable 
plaques will in fact heal and stabilize via multiple processes, 
including calcification. Although a proportion will go on to 
rupture, the majority of such events remain subclinical resulting 
in plaque growth rather than MI. As a consequence, the number 
of vulnerable plaques seems to greatly outnumber the clinical 
events that ensue (Illustration credit: Ben Smith).
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noninvasive imaging techniques that can directly image the 
disease process in a patient’s coronary arteries and, therefore, 
provide more personalized estimates of risk.
The atherosclerotic plaque burden can be measured using 
several simple and inexpensive imaging approaches. These 
predict adverse cardiovascular events presumably on the basis 
that the more plaques a patient has, the more likely one will 
rupture or erode and cause an event. Computed tomographic 
(CT) calcium scoring quantifies the amount of macroscopic 
calcification in the coronary arteries. This provides a surrogate 
of the total coronary atherosclerotic plaque burden and im-
proves risk prediction models when added to the Framingham 
risk scores.12–14 More detailed plaque assessments are now 
available with coronary CT angiography, allowing visualiza-
tion of both calcified and noncalcified plaque, as well as ad-
verse plaque characteristics.6,15 Yet, despite these considerable 
technological advances, individual risk prediction remains 
limited.
Molecular Imaging of Disease Activity
A limitation of anatomic plaque assessments is that although 
they provide an indication as to how much plaque has accu-
mulated over time, they give no indication as to the current 
activity of the disease process. They are, therefore, unable to 
distinguish those patients who have burnt-out, stable disease 
that is no longer metabolically active versus those with ac-
tive atheroma. This is of potential importance because patients 
with active disease will develop multiple unstable plaques 
over time; and although the majority will heal without inci-
dent, overall there will be an increased probability that one 
will rupture when the blood is thrombogenic and cause an 
event. The poor prognosis associated with an active disease 
process was first suggested by studies investigating disease 
progression. Raggi et al16 demonstrated the added value of 
examining the progression in plaque burden compared with 
one-off baseline measures. In a cohort of patients treated with 
statin therapy who underwent serial CT calcium scoring those 
who demonstrated <15% annual progression in their CT cal-
cium score had an excellent prognosis with few events irre-
spective of their baseline plaque burden. By contrast, subjects 
who demonstrated >15% change in their calcium score had an 
adverse prognosis, which increased progressively depending 
on their baseline disease burden. Although >10-year old, this 
study was consistent with the hypothesis that subjects with 
increased disease activity and greater rates of progression are 
more likely to have events.
Changes in the CT calcium score provide only an indi-
rect measure of disease activity and require serial imaging. 
Improved clinical imaging methods are, therefore, required to 
measure disease activity directly. The emergence of molecu-
lar imaging now allows us to do exactly that. Molecular trac-
ers targeted to pathological processes of interest are injected 
into the body, where they accumulate at sites of increased 
disease activity. These tracers are labeled with an imaging re-
porter that provides signal on the relevant imaging platform. 
Potentially, the activity of any disease process can be assessed 
depending on the availability of a suitable imaging tracer and 
scanner. However in practice, the strict requirements of the US 
Food and Drug Administration (FDA) for regulatory approval 
make the development of novel clinical tracers both time con-
suming and expensive. Human research has, therefore, largely 
focused on tracers already approved for noncardiac conditions 
but which target disease processes relevant to atherosclerosis 
and acute plaque rupture. In particular, markers of inflam-
mation and microcalcification activity have been evaluated. 
These are discussed in detail here, although an array of other 
tracers targeting processes such as angiogenesis, hypoxia, and 
plaque hemorrhage are also in development.17–19
Ultrasmall Particles of Iron Oxide Imaging of 
Inflammation
Macrophages play a pivotal role in the destabilization of ath-
erosclerotic plaques, secreting fibrous cap–degrading matrix 
metalloproteinases, proinflammatory cytokines, and pro-
thrombotic tissue factor.20 These then weaken the fibrous cap 
and drive growth of the necrotic core, increasing the propen-
sity to plaque rupture and clinical events. Multiple molecular 
imaging techniques have been developed to measure inflam-
matory activity in atherosclerosis (Figure 2).
Macrophages can be imaged directly using iron oxide con-
trast agents that have superparamagnetic properties on T2*-
weighted sequences. Iron oxide is clinically approved for the 
treatment of iron deficiency anemia, and although concerns 
have been expressed about the risk of hypersensitivity reac-
tions leading to restricted availability in the United States, 
these seem less of an issue at the lower doses used in imag-
ing. After injection of ultrasmall superparamagnetic particles 
of iron oxide (USPIO), these particles are removed from the 
circulation by the reticuloendothelial system and accumulate 
in macrophages present in atherosclerotic plaques. Iron oxide 
causes distortion in the magnetic resonance signal, which can 
be used to localize USPIO accumulation and to estimate the 
macrophage burden in a range of disease processes, including 
atherosclerosis, abdominal aortic aneurysms, and myocardial 
infarction.22–24
Kooi et al25 studied 11 symptomatic patients scheduled 
for carotid endarterectomy with USPIO-enhanced magnetic 
resonance, and they found a 24% decrease in signal intensity 
in the culprit vessel on T2*-weighted sequences, with histo-
logical evidence of USPIO uptake in 75% of these plaques 
post surgery. The USPIO signal also seems to be modifiable 
with drug therapy and, therefore, may be of value in assessing 
the anti-inflammatory properties of atherosclerotic therapies. 
Tang et al26 showed that the intensity of the USPIO signal 
could be reduced by 3 months of statin therapy, and that this 
reduction was increased with high- versus low-dose statin. 
Current limitations of USPIO-enhanced magnetic resonance 
imaging with agents such as ferumoxtran are the need for 
2 scans, one before USPIO administration and another one 
≈36 hours after injection.27 Accurate coregistration is then 
required to detect differences in the T2* signal because of 
USPIO accumulation. This can be challenging in complex 
3-dimensional vascular structures. Moreover, T2* artifact 
and high blood pool activity are frequently observed, making 
the detection of true signal in atherosclerotic plaques diffi-
cult. Although these issues can largely be overcome in the ca-
rotids and aorta, they currently preclude imaging in the small 
and constantly moving coronary arteries.
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Positron Emission Tomography Imaging of 
Inflammation Activity
Positron emission tomography (PET) is a nuclear imaging 
modality used for a variety of clinical purposes. It is ideally 
suited to measure disease activity, using radiolabeled trac-
ers targeted to specific pathological processes. PET trac-
ers combine a positron emitter (usually 18F because of its 
advantageous half-life) with a molecular vehicle targeting 
the cellular process of interest. After injection, these tracers 
accumulate in areas of disease activity, emitting positrons, 
which collide with nearby electrons. This collision results in 
particle annihilation and the release of a pair of photons with 
a specific energy. Simultaneous detection of these paired pho-
tons allows the PET scanner to localize tracer accumulation 
with exquisite sensitivity and a spatial resolution of ≈4 mm. 
Two tracers, in particular, hold promise in assessing athero-
sclerosis: 18F-fluorodeoxyglucose (18F-FDG) as a marker of 
inflammation activity28 and 18F-fluoride as a marker of newly 
forming microcalcification.29 These tracers are used for the 
routine clinical imaging of oncology patients. They are, there-
fore, FDA approved, commercially available, inexpensive, 
and have established excellent safety records.
18F-FDG PET
18F-FDG is a PET tracer and glucose analog that is taken 
up by metabolically active cells. On this basis, it has become 
widely used to image cancer but more recently has been used 
as a marker of vascular inflammation given that macrophages 
use more glucose than surrounding cells, particularly in hy-
poxic conditions.30
18F-FDG PET has been most extensively investigated 
in the carotid arteries and aorta (Figure 2) with uptake cor-
relating with macrophage burden in excised carotid plaques31 
and multiple adverse imaging plaque characteristics.32,33 
Importantly, accumulating data demonstrate the prognos-
tic value of 18F-FDG PET, albeit largely in the form of 
single-center, retrospective studies. In the Dublin Carotid 
Atherosclerosis Stroke Study, carotid artery inflammation de-
tected by 18F-FDG was useful for identifying patients most 
at risk of early stroke recurrence.34 In another retrospective 
study of 513 patients without cancer, inflammatory disease 
or previous cardiovascular disease but who underwent PET 
imaging for oncological evaluation, the aortic 18F-FDG PET 
signal again provided independent prediction of cardiovascu-
lar events after a median follow-up of 4.2 years (hazard ra-
tio, 4.71, P<0.001).35 Similarly, in 1089 asymptomatic adults 
being screened for cancer increased carotid 18F-FDG uptake 
predicted future stroke with incremental value above FRS.36
Scan–rescan reproducibility of the vascular 18F-FDG sig-
nal is excellent37 and coupled with the established mechanistic 
and prognostic data available for this tracer; 18F-FDG PET 
is increasingly being used as an end point in trials of novel 
atherosclerosis therapies. The excellent reproducibility means 
that such studies require relatively few patients (n=30–50) 
to demonstrate an anti-inflammatory treatment effect, which 
can be observed quickly after drug initiation (3–6 months). 
Vascular 18F-FDG studies are, therefore, relatively low cost 
and time efficient, serving as an economical introduction to 
larger and more expensive clinical end point trials. The ben-
eficial effects of statin therapy are well documented, so it is 
reassuring that statins have demonstrated a consistent and 
clear reduction in the vascular 18F-FDG PET signal, pro-
portional to the dose of statin used.38–40 In contrast, inhibitors 
of lipoprotein-associated phospholipase A2, failed to modify 
both the vascular 18F-FDG signal and the hard clinical end 
points.41,42 Similarly, dalcetrapib, a cholesteryl ester transfer 
Figure 2. Molecular imaging of vascular inflammation 
activity. A, 18F-fluorodeoxyglucose (18F-FDG) positron 
emission tomography (PET) image fused with contrast computed 
tomographic (CT) angiogram of the thoracic aorta, demonstrating 
regions of increased activity in the ascending aorta (blue), 
aortic arch (green), and descending aorta (red). B, 18F-FDG 
PET/magnetic resonance (MR) image of the carotid arteries 
demonstrating increased activity in the left carotid artery and the 
excellent soft tissue contrast provided by MR. C, 18-FDG PET 
fused with a CT coronary angiogram demonstrating increased 
uptake in the left ventricle but also in a remote plaque in the mid 
right coronary artery. Image in panel C reproduced from Cheng 
et al21 with permission of the publisher. Copyright © 2012, the 
Society of Nuclear Medicine and Molecular Imaging, Inc. D, 
68Ga-DOTATATE PET/CT image with increased activity localizing 
to a plaque in the mid left anterior descending artery. E, T2* Map 
from patients with an abdominal aortic aneurysm that had been 
administered ultra small particles of iron oxide (USPIO). A hot 
spot is observed in the anterior wall of the aneurysm (arrow). 
F, In a second patient, focal areas of increased USPIO uptake 
can be observed (the increased signal adjacent to the lumen is 
considered normal because of high signal in the blood pool). 
Images in panels E and F reproduced from Richards et al23 with 
permission of the publisher. Copyright © 2011, Wolters Kluwer 
Health, Inc.
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protein inhibitor, demonstrated no impact on either vascular 
18F-FDG activity nor clinical events.43,44
Translation of 18F-FDG imaging in to the coronary ar-
teries has proved more challenging. This is because glucose 
is the predominant energy source of the myocardium, such 
that avid uptake of 18F-FDG by the left ventricle is frequently 
observed. Although myocardial 18F-FDG uptake can be sup-
pressed by dietary restrictions (that aim to switch myocardial 
metabolism from glucose to free fatty acids), this is ineffec-
tive in 20% to 30% of cases. Indeed in a recent study, >50% 
of the coronary territories assessed were not interpretable 
because of spill over of myocardial 18F-FDG uptake.45 Until 
improved methods of myocardial suppression are developed, 
this is likely to limit the assessment of 18F-FDG uptake in 
individual coronary plaques. It may, however, be possible to 
measure more generalized 18F-FDG uptake in the proximal 
coronary vessels or the ascending aorta. Rogers et al46 studied 
post-acute coronary syndrome in 10 patients, demonstrating 
the increased uptake in the left main stem and ascending aorta 
compared with 15 patients with stable angina. Similarly, Joshi 
et al47 demonstrated increased 18F-FDG uptake in the thoracic 
aorta of 40 patients after myocardial infarction compared with 
40 stable patients, despite similar plaque burden. Whether 
this increased vascular inflammation activity represents the 
cause or effect of the acute infarct remains to be established, 
although a correlation was observed between infarct size and 
aortic 18F-FDG uptake,47 consistent with the latter interpreta-
tion and recent preclinical data.48
Alternative PET tracers
The fact that reliable coronary evaluation with 18F-FDG 
is often not possible because of high myocardial muscle 
uptake, coupled with its inherent lack of cellular speci-
ficity, drives the search for alternative PET tracers tar-
geting atherosclerotic inflammation. 68Ga-DOTATATE 
([1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic 
acid]-d-Phe(1),Tyr(3)-octreotate) is a PET tracer with high 
specific binding affinity for the somatostatin receptor sub-
type-2 (≈0.2 nmol/L), which is currently used clinically for 
neuroendocrine tumor imaging. Upregulation of the soma-
tostatin receptor subtype-2 seems to occur on the cell surface 
of activated macrophages, offering a potential novel imag-
ing target for tracking vascular inflammation. Initial studies 
are encouraging, and there is some histological evidence in 
mice showing significant correlation between the aortic 68Ga-
DOTATATE PET signal and macrophage density (%CD68 
staining).49 In a retrospective study, Rominger et al50 observed 
detectable 68Ga-DOTATATE uptake in the left anterior de-
scending artery in each of the 70 patients evaluated, with 
increased tracer activity seen among patients with coronary 
calcification or a history of cardiovascular events. In another 
retrospective study, increased vascular 68Ga-DOTATATE up-
take was, again, observed in the aorta, carotid and iliac arter-
ies in patients with cardiovascular risk factors and coronary 
calcification.51 Although low myocardial binding of 68Ga-
DOTATATE is advantageous for coronary imaging, high 
physiological liver uptake can potentially obscure interpreta-
tion of signals originating for the distal right coronary artery. 
The use of this tracer for atherosclerosis imaging is being 
studied in more detail in the ongoing prospective Vascular 
Inflammation Imaging Using Somatostatin Receptor Positron 
Emission Tomography (VISION) study (ClinicalTrial.gov 
NCT02021188).
11C-PK11195 is one of the several PET tracers targeting 
the translocator protein, a receptor that is highly expressed 
on the surface of macrophages. This family of tracers has, 
therefore, also been used to target vascular inflammation.52,53 
Fujimura et al54 showed specific binding of 3H-PK11195 to 
macrophages in human carotid atheroma, although Pugliese 
et al55 demonstrated increased 11C-PK11195 PET activity in 
patients with symptomatic large-vessel vasculitis. Gaemperli 
et al53 demonstrated increased activity of 11C-PK11195 in 
culprit carotid plaques poststroke with uptake localizing to 
macrophages and translocator protein expression on histol-
ogy. However, using 11C in clinical studies is challenging be-
cause of its half-life, so that 18F-labeled translocator protein 
tracers are keenly anticipated, although issues also surround 
genetic polymorphisms that seem to have a major effect on 
tracer-binding affinity.
Finally, PET imaging with 18F-fluorodeoxymannose has 
recently been described in a preclinical study.56 Mannose is an 
isomer of glucose, and the mannose receptor is upregulated on 
alternatively activated or M2 macrophages in high-risk plaque. 
There is, therefore, hope that 18F-fluorodeoxymannose PET 
may provide improved detection of such lesions. Macrophages 
demonstrate a 35% increase in tracer uptake compared with 
18-FDG, with a similar pattern of vascular uptake in a rab-
bit model of atherosclerosis.56 Further studies are awaited, al-
though they may be limited by the difficulties in radiolabeling 
mannose.
The Link Between Inflammation and Calcification
The exact role of calcification in atherosclerosis remains to 
be defined. Although significant progress in our understand-
ing has been achieved over recent years, many of the proposed 
mechanisms described below requires confirmation by future 
studies.
Emerging evidence suggests that intimal calcification oc-
curs as a healing response to intense inflammation and cell 
death within the atherosclerotic plaque, mediated by extra-
cellular vesicles (Figure 3). It seems to be a different disease 
process to the medial calcification often unassociated with 
inflammation and more commonly observed in the larger ar-
teries of patients with renal failure and altered calcium me-
tabolism (eg, patients on dialysis and osteoporosis).57 In the 
coronary arteries, intimal calcification predominates. Using 
longitudinal molecular imaging studies, Aikawa et al58 linked 
inflammation and intimal calcification in a mouse model of 
atherosclerosis, demonstrating a close association between 
the early stages of in vivo microcalcification and macrophage 
inflammatory activity (R2=0.93). The link between inflamma-
tion and calcification also seems closely related to cell death 
within the plaque and the release of extracellular vesicles.59–61 
These pathological extracellular vesicles are loaded with pro-
osteogenic mediators (eg, proteins and micro-RNAs), contain-
ing high concentrations of calcium and phosphate, and seem 
to act as nucleation sites for the formation of hydroxyapatite 
crystal.9,62–64 Extracellular vesicles, recently demonstrated to 
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be of exosomal origin, are released directly by inflammatory 
macrophages65 and by vascular smooth muscle cells, imply-
ing that atherosclerotic plaques contain a continuous source 
of the precursors to microcalcification.9,64 Concurrent with this 
process, a range of resident vascular and recruited progeni-
tor cells differentiate into those with an osteoblastic or chon-
drocytic phenotypes. This differentiation process seems to be 
associated with inflammation, promoted by proinflammatory 
cytokines, particularly tumor necrosis factor-α.59 These pro-
calcific cells then provide an alternative source of calcifying 
extracellular vesicles, driving the ongoing formation of micro-
calcifications until large stable sheets of macroscopic calcifi-
cation develop.
Differences Between Microcalcification and 
Macrocalcification
The presence of calcium in the coronary arteries can have di-
verse clinical implications. It is useful to consider calcification 
as a 2-phase process: the initial stage of microcalcification and 
the end stages of macroscopic calcium formation (Figure 3).66 
Macroscopic calcific deposits are traditionally associated with 
plaque stability, supported by recent models of mechanical 
stress.67 Indeed, we consider them to represent the end stage 
of the healing process, effectively walling off the inflamed 
plaque contents in a process similar to other intense inflam-
matory conditions, such as tuberculosis. These large deposits 
are readily identified by CT. Indeed, CT calcium scoring is a 
powerful predictor of coronary events.68 Of note, extensively 
calcified plaques themselves only rarely result in rupture and 
adverse events, but rather calcium scoring acts as a biomarker 
of overall disease and coronary plaque burden.
By comparison, microcalcification represents the early 
stages of intimal calcium formation and is associated with 
high risk and culprit atherosclerotic plaque in histopathologic 
and imaging studies alike.69–73 This may, in part, reflect the 
close relationship between the microcalcification and the in-
flammation thought to act as its trigger.58 However, recent data 
have suggested that microcalcification might itself directly 
contribute to plaque rupture, greatly amplifying mechanical 
stresses on the surface of the fibrous plaque.74,75 In particular, 
deposits ranging between 5 and 60 µm are associated with an 
increase in local stresses >500%.75,76 Whether directly or indi-
rectly, microcalcification, therefore, seems closely related to 
the processes driving plaque rupture and although it remains 
beyond the resolution of CT, these structures can now be de-
tected noninvasively using molecular imaging.
PET Imaging of Microcalcification Activity
18F-fluoride has been used safely as a PET bone tracer for 
over 40 years but has only recently been assessed in the vas-
culature. Indeed, the first description was in 2010 by Derlin 
et al77 who retrospectively studied patients who had been 
scanned for investigation of cancer. They described increased 
uptake in the aorta, carotids and femoral vessels in 57 of the 
75 patients studied. Although sites of 18F-fluoride uptake 
were commonly observed in close association with regions of 
existing calcium on CT, increased uptake was also observed in 
their absence. Moreover, the vast majority of calcific lesions 
on CT did not demonstrate increased 18F-fluoride uptake, 
suggesting that the 2 approaches provide different informa-
tion about vascular calcification. The same group went on to 
establish an association between femoral 18F-fluoride uptake 
and cardiovascular risk factors78 and to demonstrate that this 
tracer provides distinct information to 18F-FDG.79
Although these studies provided early insight, the exact 
mechanisms underlying 18F-fluoride uptake in the vascula-
ture have only recently been elucidated. Irkle et al29 provided 
comprehensive assessment of carotid endarterectomy samples 
using electron microscopy, autoradiography, histology, and 
preclinical and clinical PET/CT to analyze 18F-fluoride bind-
ing. They demonstrated that 18F-fluoride adsorbs to calcified 
deposits within plaque with high affinity and is both selective 
and specific. Moreover, 18F-fluoride was able to distinguish 
between areas of macro- and microcalcification, binding pref-
erentially to the latter. It, therefore, provided differential infor-
mation to CT, which was only able to detect large macroscopic 
Figure 3. The link between inflammation, 
microcalcification, and macrocalcification. 
A large necrotic core, a thin fibrous cap, and an 
intense inflammation are key precipitants of acute 
plaque rupture and myocardial infarction. Intimal 
calcification is thought to occur as a healing 
response to this intense necrotic inflammation. 
However, the early stages of microcalcification 
(detected by 18F-fluoride positron emission 
tomography) are conversely associated with an 
increased risk of rupture. In part, this is because of 
residual plaque inflammation and in part because 
microcalcification itself increases mechanical stress 
in the fibrous cap further increasing propensity 
to rupture. With progressive calcification, plaque 
inflammation becomes pacified and the necrotic 
core walled off from the blood pool. The latter 
stages of macrocalcification (detected by 
computed tomographic) are, therefore, associated 
with plaque stability and a lower risk of that plaque 
rupturing (Illustration credit: Ben Smith).
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deposits. Indeed, 18F-fluoride is the only currently available 
clinical imaging platform that can noninvasively detect micro-
calcification in active unstable atheroma. The explanation for 
18F-fluoride’s preferential binding to microcalcification is the 
high surface area of hydroxyapatite in these nanocrystalline 
areas. By comparison, in large macroscopic deposits, much of 
the hydroxyapatite is internalized and not available for bind-
ing so that 18F-fluoride uptake is only observed at the periph-
ery (Figure 4).
Behesti et al80 first described 18F-fluoride activity in the 
heart, with further studies localizing this activity to the valves 
of patients with aortic stenosis81,82 and to individual coronary 
plaques.83 In aortic stenosis, isolated 18F-fluoride uptake pre-
dicts the location of future macroscopic calcium formation 
on CT, accurately predicting progression of the aortic valve 
CT calcium score,84,85 and correlating with alkaline phospha-
tase activity on histology.85 18F-fluoride, therefore, acts as a 
marker of vascular calcification activity in aortic stenosis, ap-
pearing to bind to newly forming microcalcification within the 
valve leaflets.86
In the coronary arteries, 18F-fluoride is the first tracer to 
localize to individual coronary plaques with little background 
activity and excellent signal-to-noise ratio (Figure 5).83 Those 
plaques demonstrating increased 18F-fluoride uptake have 
multiple high-risk characteristics when assessed with virtual 
histology intravascular ultrasound, including microcalcifica-
tion, positive remodeling, and a large necrotic core, findings 
confirmed in pathological validation studies of the carotid ar-
teries.45 18F-fluoride also seems to localize to ruptured culprit 
plaque post myocardial infarction. In a study of 40 patients 
who had a recent myocardial infarction, 37 demonstrated 
increased uptake in their adjudicated culprit plaque.45 This 
would suggest that microcalcification is indeed implicated in 
atherosclerotic plaque rupture, although it remains impossible 
to know whether increased 18F-fluoride activity was truly 
present before the rupture event or whether it developed in 
response. Moreover for the reasons discussed above, it would 
seem likely that in observational cohort studies, the majority of 
18F-fluoride–positive plaques would heal, rather than causing 
events. Nevertheless 18F-fluoride holds promise in improving 
our understanding of the pathophysiology of atherosclerosis 
and in predicting events at the patient level. Indeed, the ability 
of hybrid 18F-fluoride PET/CT to predict disease progression 
and to identify patients at risk of myocardial infarction is cur-
rently being tested in a large multicenter and prospective ob-
servational study, PREFFIR (Prediction of Recurrent Events 
With 18F-Fluoride; ClinicalTrial.gov NCT02278211).
Hybrid Coronary Imaging
Given the highly complex, multifaceted pathophysiology 
underlying atherosclerosis and its progression to plaque rup-
ture and myocardial infarction, accurate risk prediction may 
well depend on a similarly multifaceted imaging approach, 
simultaneously assessing a range of pathophysiological and 
prognostic factors. Hybrid cardiovascular imaging has the po-
tential to provide exactly that information. PET/CT scanners 
incorporate both CT and PET within the same gantry allowing 
sequential imaging with the patient in the same position. The 2 
images can then be fused and used to provide complimentary 
information: anatomy from the CT and disease activity from 
PET. Progressively, more complex imaging protocols have 
been introduced combining CT calcium scoring, contrast CT 
angiography, and PET motion correction so that a single scan 
can potentially provide an assessment of plaque burden, high-
risk plaque characteristics, luminal obstruction, and disease 
activity. The hope is that the combined predictive capability 
Figure 4. 18F-Fluoride preferentially binds microcalcification beyond the resolution of computed tomography (CT). Images are 
taken ex vivo of a carotid endarterectomy specimen excised from a patient who had a recent stroke. A, Histological section of the excised 
plaque stained for calcium with Alizarin red. B, Filled black arrow shows an area of dense macroscopic calcification that is visible on 
micro-CT. By comparison, the empty black arrow head demonstrates areas of microcalcification that are beyond the resolution of the 
micro-CT but by comparison demonstrate avid binding with 18F-fluoride on both autoradiography (C) and micro–positron emission 
tomography imaging (D). E, A second carotid endarterectomy sample from a patient post stroke demonstrates a large macro calcific 
deposit on micro-CT. F, Autoradiography shows that although 18F-fluoride is able to bind to the surface of the plaque, it is unable to 
penetrate in to the center. As a consequence of this effect, 18-fluoride binds preferentially to regions of microcalcification compared with 
macroscopic deposits. Reprinted from Irkle et al29 with permission. Copyright © 2015, Macmillan Publishers Limited.
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of these parameters will facilitate highly accurate prognostic 
models, allowing systemic therapies to be targeted to patients 
at highest risk and reducing the incidence of future myocardial 
infarction (Figure 4). Again this combined strategy will be as-
sessed in PREFFIR.
Optimization of Coronary PET Imaging
Further work is required to optimize 18F-fluoride imaging in 
the coronary arteries. This is made particularly difficult by both 
the effects of coronary motion and the small caliber of these 
vessels, causing partial voluming.87 ECG gating improves lo-
calization of the signal to the coronary arteries but discards 
75% of the data increasing noise.45 New image analysis tech-
niques model and then correct for both cardiac and respira-
tory motion without discarding any data, allowing improved 
localization, increased signal and reduce noise.88 Background 
18F-fluoride uptake in the coronary arteries seems lower than 
in the blood pool of the right atrium because of the partial 
voluming and the influence of low uptake in the adjacent 
lungs and myocardium. Further work is required to account 
for this issue and to determine the best method for quantifying 
coronary 18F-fluoride uptake and whether increased activity 
is present. For example, it remains unclear if the correcting 
coronary activity for background uptake in the blood pool 
or adjacent coronary vasculature is preferable. Moreover, al-
though 18F-fluoride preferentially binds newly developing 
areas of microcalcification, there remains some binding to the 
surface of large macroscopic deposits, suggesting that coro-
nary uptake should perhaps also account for the underlying 
CT calcium score. The scan–rescan reproducibility of these 
image analysis approaches also needs to be established be-
fore studies examining how the coronary 18F-fluoride signal 
changes with time are performed. Finally, a potential barrier 
to the future application of PET/CT is the associated high-
radiation exposure (≈10 mSV). This is likely to preclude se-
rial imaging of patients and limit our ability to track disease 
progression and response to therapy. Although CT radiation 
doses are being reduced rapidly, an alternative approach is to 
use PET/magnetic resonance imaging that might not only re-
duce radiation by ≤70% but also improve motion correction 
and avoid the need for contrast administration.89,90
Conclusions
Concerns have emerged with imaging strategies aimed at 
identifying individual vulnerable plaques in the coronary 
arteries. There is hope that newer strategies providing more 
Figure 5. 18F-fluoride PET imaging in the coronary arteries. Multiple examples of 18F-fluoride localizing to individual coronary plaques 
on fused positron emission tomography/computed tomography images of the heart. This can be observed in the left anterior descending 
artery (A, B, E, G, I, J, and K), circumflex (F and H) and right coronary arteries (C and L), and in a saphenous vein graft (D).
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global assessments of disease activity across the vasculature 
will lead to improved risk prediction, differentiating patients 
with truly stable disease compared with those with active 
potentially unstable atheroma. These strategies have largely 
focused on imaging inflammation in larger arteries and more 
recently microcalcification in the coronary arteries providing 
important pathophysiological insight and with the potential 
to ultimately influence patient management. However, these 
relatively expensive techniques will need to demonstrate both 
added value to risk instruments based on soluble biomark-
ers and traditional risk factors and ultimately that their use is 
clinically effective in reducing cardiovascular events within 
rigorous large-scale clinical trials.
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